Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Increasing Mortality Among Patients With Diabetes and Chronic Liver Disease From 2007 Through 2017.

Kim D, Cholankeril G, Kim SH, Abbasi F, Knowles JW, Ahmed A.

Clin Gastroenterol Hepatol. 2019 Jun 17. pii: S1542-3565(19)30649-4. doi: 10.1016/j.cgh.2019.06.011. [Epub ahead of print] No abstract available.

PMID:
31220638
2.

Pre-Operative Delta-MELD is an Independent Predictor of Higher Mortality following Liver Transplantation.

Cholankeril G, Li AA, Dennis BB, Gadiparthi C, Kim D, Toll AE, Maliakkal BJ, Satapathy SK, Nair S, Ahmed A.

Sci Rep. 2019 Jun 5;9(1):8312. doi: 10.1038/s41598-019-44814-y.

3.

Hepatocellular carcinoma is leading in cancer-related disease burden among hospitalized baby boomers.

Gadiparthi C, Yoo ER, Are VS, Charilaou P, Kim D, Cholankeril G, Pitchumoni C, Ahmed A.

Ann Hepatol. 2019 May 21. pii: S1665-2681(19)30343-6. doi: 10.1016/j.aohep.2019.04.014. [Epub ahead of print]

4.

Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014.

Kim D, Cholankeril G, Li AA, Kim W, Tighe SP, Hameed B, Kwo PY, Harrison SA, Younossi ZM, Ahmed A.

Liver Int. 2019 May 13. doi: 10.1111/liv.14135. [Epub ahead of print]

PMID:
31081997
5.

Trends in overall, cardiovascular and cancer-related mortality among individuals with diabetes reported on death certificates in the United States between 2007 and 2017.

Kim D, Li AA, Cholankeril G, Kim SH, Ingelsson E, Knowles JW, Harrington RA, Ahmed A.

Diabetologia. 2019 Jul;62(7):1185-1194. doi: 10.1007/s00125-019-4870-9. Epub 2019 Apr 22.

PMID:
31011776
6.

Elevated urinary bisphenol A levels are associated with non-alcoholic fatty liver disease among adults in the United States.

Kim D, Yoo ER, Li AA, Cholankeril G, Tighe SP, Kim W, Harrison SA, Ahmed A.

Liver Int. 2019 Mar 29. doi: 10.1111/liv.14110. [Epub ahead of print]

PMID:
30924602
7.

The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD.

Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A.

Diseases. 2019 Feb 25;7(1). pii: E27. doi: 10.3390/diseases7010027. Review.

8.

Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016.

Kim D, Kim W, Adejumo AC, Cholankeril G, Tighe SP, Wong RJ, Gonzalez SA, Harrison SA, Younossi ZM, Ahmed A.

Hepatol Int. 2019 Mar;13(2):205-213. doi: 10.1007/s12072-018-09926-z. Epub 2019 Jan 29.

PMID:
30694445
9.

Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft.

Liu A, Galoosian A, Kaswala D, Li AA, Gadiparthi C, Cholankeril G, Kim D, Ahmed A.

J Clin Transl Hepatol. 2018 Dec 28;6(4):420-424. doi: 10.14218/JCTH.2018.00010. Epub 2018 Jul 28. Review.

10.

Use of anti-platelet agents in the prevention of hepatic fibrosis in patients at risk for chronic liver disease: a systematic review and meta-analysis.

Iqbal U, Dennis BB, Li AA, Cholankeril G, Kim D, Khan MA, Ahmed A.

Hepatol Int. 2019 Jan;13(1):84-90. doi: 10.1007/s12072-018-9918-2. Epub 2018 Dec 12.

PMID:
30539518
11.

Low-Normal Thyroid Function Is Associated With Advanced Fibrosis Among Adults in the United States.

Kim D, Yoo ER, Li AA, Fernandes CT, Tighe SP, Cholankeril G, Hameed B, Ahmed A.

Clin Gastroenterol Hepatol. 2018 Nov 17. pii: S1542-3565(18)31267-9. doi: 10.1016/j.cgh.2018.11.024. [Epub ahead of print]

PMID:
30458247
12.

Disparate Trends in Mortality of Etiology-Specific Chronic Liver Diseases Among Hispanic Subpopulations.

Kim D, Li AA, Perumpail RB, Cholankeril G, Gonzalez SA, Kim W, Ahmed A.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1607-1615.e2. doi: 10.1016/j.cgh.2018.10.045. Epub 2018 Nov 1.

PMID:
30391436
13.

Association of Pretransplant Renal Function With Liver Graft and Patient Survival After Liver Transplantation in Patients With Nonalcoholic Steatohepatitis.

Molnar MZ, Joglekar K, Jiang Y, Cholankeril G, Abdul MKM, Kedia S, Gonzalez HC, Ahmed A, Singal A, Bhamidimarri KR, Aithal GP, Duseja A, Wong VW, Gulnare A, Puri P, Nair S, Eason JD, Satapathy SK; Global NAFLD Consortium.

Liver Transpl. 2019 Mar;25(3):399-410. doi: 10.1002/lt.25367.

PMID:
30369023
14.

An Unexpected Colonic Mass.

Li AA, Cholankeril G, Berry GJ, Fernandez-Becker N.

Am J Gastroenterol. 2019 Jan;114(1):180-181. doi: 10.1038/s41395-018-0363-6. No abstract available.

15.

Temporal Trends Associated With the Rise in Alcoholic Liver Disease-related Liver Transplantation in the United States.

Cholankeril G, Gadiparthi C, Yoo ER, Dennis BB, Li AA, Hu M, Wong K, Kim D, Ahmed A.

Transplantation. 2019 Jan;103(1):131-139. doi: 10.1097/TP.0000000000002471.

PMID:
30300285
16.

When to Initiate Weight Loss Medications in the NAFLD Population.

Yoo ER, Sallam S, Perumpail BJ, Iqbal U, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A.

Diseases. 2018 Sep 30;6(4). pii: E91. doi: 10.3390/diseases6040091. Review.

17.

Increasing Trends in Transplantation of HCV-Positive Livers Into Uninfected Recipients.

Cholankeril G, Li AA, Dennis BB, Toll AE, Kim D, Bonham CA, Nair S, Ahmed A.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1634-1636. doi: 10.1016/j.cgh.2018.09.036. Epub 2018 Sep 27.

PMID:
30268562
18.

Judicious Use of Lipid Lowering Agents in the Management of NAFLD.

Iqbal U, Perumpail BJ, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A.

Diseases. 2018 Sep 24;6(4). pii: E87. doi: 10.3390/diseases6040087. Review.

19.

The Role of Vitamin E in the Treatment of NAFLD.

Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A.

Diseases. 2018 Sep 24;6(4). pii: E86. doi: 10.3390/diseases6040086. Review.

20.

Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD.

Dibba P, Li AA, Perumpail BJ, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A.

Diseases. 2018 Sep 19;6(3). pii: E83. doi: 10.3390/diseases6030083. Review.

Supplemental Content

Loading ...
Support Center